VOL. XCIV, NO. 247
★ WIDE MOAT STOCKS COMPARISON ★
NO ADVICE
Thursday, January 8, 2026
Stock Comparison
Gilead Sciences, Inc. vs TMX Group Limited
Compare moat strength, market structure, and segment coverage to understand how each company defends its edge.
Gilead Sciences, Inc.
GILD · NASDAQ Global Select Market
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into Gilead Sciences, Inc.'s moat claims, evidence, and risks.
View GILD analysisTMX Group Limited
X · Toronto Stock Exchange
Weighted average of segment moat scores, combining moat strength, durability, confidence, market structure, pricing power, and market share.
Full stock profile
Dive deeper into TMX Group Limited's moat claims, evidence, and risks.
View X analysisComparison highlights
- Moat score gap: Gilead Sciences, Inc. leads (74 / 100 vs 70 / 100 for TMX Group Limited).
- Segment focus: Gilead Sciences, Inc. has 5 segments (68.5% in HIV); TMX Group Limited has 9 segments (16.1% in Trayport energy trading workflow software and network).
- Moat breadth: Gilead Sciences, Inc. has 8 moat types across 3 domains; TMX Group Limited has 12 across 5.
Primary market context
Gilead Sciences, Inc.
HIV
HIV treatment and prevention medicines (antiretroviral therapy and PrEP)
Global (U.S. and Europe are major markets)
Patients/prescribers; reimbursed by public and private payers; distributed via wholesalers and specialty pharmacies
Drug developer and marketing authorization holder
68.5%
TMX Group Limited
Trayport energy trading workflow software and network
Wholesale energy trading workflow software and network connectivity
Europe-centric, with global customers
Energy traders, brokers, exchanges/venues
Interoperability hub / workflow platform
16.1%
Side-by-side metrics
Moat coverage
Shared moat types
Gilead Sciences, Inc. strengths
TMX Group Limited strengths
Segment mix
Gilead Sciences, Inc. segments
Full profile >HIV
Oligopoly
Oncology (Cell Therapy + Trodelvy)
Oligopoly
Liver Disease
Oligopoly
Veklury (Remdesivir)
Competitive
Other Products
Competitive
TMX Group Limited segments
Full profile >TSX & TSXV listing and sustaining fees
Oligopoly
Issuer services (TSX Trust and TMX Newsfile)
Competitive
Equities and fixed income trading venues (TSX, TSXV, TSX Alpha, Shorcan)
Oligopoly
Post-trade clearing, settlement and depository (CDS / CDSX)
Quasi-Monopoly
Canadian listed derivatives trading and clearing (Montreal Exchange + CDCC, excl. BOX)
Quasi-Monopoly
U.S. equity options exchange (BOX)
Competitive
Trayport energy trading workflow software and network
Oligopoly
TMX Datalinx market data and co-location
Quasi-Monopoly
TMX VettaFi indexing, ETF analytics, and digital distribution
Oligopoly
Want the full wide moat stocks list?
Browse the full ranking of wide moat stocks, updated with moat scores and segment context.
View the moat stocks listLooking for expansion-stage stocks?
Proven models entering the expansion stage with unit economics that work.
View expansion-stage stocksCuration & Accuracy
This directory blends AI‑assisted discovery with human curation. Entries are reviewed, edited, and organized with the goal of expanding coverage and sharpening quality over time. Your feedback helps steer improvements (because no single human can capture everything all at once).
Details change. Pricing, features, and availability may be incomplete or out of date. Treat listings as a starting point and verify on the provider’s site before making decisions. If you spot an error or a gap, send a quick note and I’ll adjust.